Parkinson's Disease
Conditions
Keywords
Cystatin C, PET-DAT
Brief summary
To investigate the relationship between serum cystatin C and dopamine receptor(DAT) loss in patients with parkinson's disease(PD)
Detailed description
Number of people suffered from Parkinson disease (PD) is increasing every year. PET imaging of dopamine transport receptors（DAT） serves as the gold standard for the diagnosis and monitoring of PD development. However, due to high costs and radiation reasons, it is not suitable for long-term follow-up. Serum cystatin C can be easily obtained and cheap as an indicator. In recent years, studies have gradually found that it is related to the progression of H&Y staging of Parkinson's disease. To this extent, we want to further explore whether it can reflect the loss of DAT in the brain. Explore whether it can partially replace the role of DAT imaging for future clinical evaluation.
Interventions
None listed
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged between 20 and 80 years and whose laboratory results included the levels of serum Cystatin C within a month from the PET-DAT were recruited.
Exclusion criteria
* To make the study cohort more homogeneous, PD patients with either a long-standing duration (≥5 years) or advanced Hoehn and Yahr (H&Y) staging (≥3) were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cystatin C assesses the loss of dopaminergic neurons | through study completion, an average of 1 year | Explore whether Cystatin C can respond to the loss of dopaminergic neurons |
Countries
China
Contacts
Primary ContactBaoRong Zhang, MD
Outcome results
None listed